11/20
04:00 pm
amgn
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Low
Report
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
11/20
10:06 am
amgn
Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies [Yahoo! Finance]
Low
Report
Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies [Yahoo! Finance]
11/19
10:51 am
amgn
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]
Low
Report
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]
11/18
01:17 pm
amgn
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver
Low
Report
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver
11/18
09:56 am
amgn
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
11/15
09:00 pm
amgn
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
11/15
08:04 am
amgn
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/15
05:59 am
amgn
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/14
04:37 pm
amgn
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate [Yahoo! Finance]
Medium
Report
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate [Yahoo! Finance]
11/14
04:02 pm
amgn
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 [Yahoo! Finance]
Medium
Report
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 [Yahoo! Finance]
11/14
04:00 pm
amgn
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
Medium
Report
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
11/14
08:22 am
amgn
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder [Yahoo! Finance]
Low
Report
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder [Yahoo! Finance]
11/14
07:35 am
amgn
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $335.00 price target on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $335.00 price target on the stock.
11/13
03:27 pm
amgn
MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
Low
Report
MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
11/13
02:06 pm
amgn
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density [Yahoo! Finance]
Low
Report
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density [Yahoo! Finance]
11/13
11:16 am
amgn
3 Top Dividend Stocks to Maximize Your Retirement Income [Yahoo! Finance]
Low
Report
3 Top Dividend Stocks to Maximize Your Retirement Income [Yahoo! Finance]
11/13
10:34 am
amgn
What's Happening With Amgen Stock? [Forbes]
Low
Report
What's Happening With Amgen Stock? [Forbes]
11/13
06:05 am
amgn
Amgen dismisses bone density concerns related to its new weight-loss drug [Yahoo! Finance Canada]
Low
Report
Amgen dismisses bone density concerns related to its new weight-loss drug [Yahoo! Finance Canada]
11/13
05:54 am
amgn
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight [Yahoo! Finance]
Low
Report
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight [Yahoo! Finance]
11/13
05:00 am
amgn
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
Low
Report
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
11/12
04:14 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.
11/12
08:33 am
amgn
Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.
11/11
05:34 pm
amgn
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Medium
Report
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
11/8
04:00 pm
amgn
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
Low
Report
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
11/8
04:40 am
amgn
Biosimilars Market Industry Report 2024 - Rising Demand for Biosimilars as a Cost-effective Alternative has Promoted the Need for Increased In-house Development and Outsourcing Operations [Yahoo! Finance]
Low
Report
Biosimilars Market Industry Report 2024 - Rising Demand for Biosimilars as a Cost-effective Alternative has Promoted the Need for Increased In-house Development and Outsourcing Operations [Yahoo! Finance]